ArticleInflammatory intestinal diseases2019
Tacrolimus Suppositories in Therapy-Resistant Ulcerative Proctitis.
Article in Inflammatory intestinal diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis.The Cochrane database of systematic reviews · 2022Pooled it
- Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide.Alimentary pharmacology & therapeutics · 2025Review
- Medical, Endoscopic, and Surgical Treatments for Rectal Cuffitis in IBD Patients with an Ileal Pouch-Anal Anastomosis: A Narrative Review.Digestive diseases and sciences · 2025Review
- Clinical features and current treatment approach to ulcerative proctitis.Translational gastroenterology and hepatology · 2025Review
- Systematic review: the use of tacrolimus in steroid-refractory ulcerative colitis.Therapeutic advances in chronic disease · 2025Review
- The Role of Topical Tacrolimus in the Management of Inflammatory Bowel Disease: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Cross-tissue transcriptome-wide association studies identify susceptibility genes shared between schizophrenia and inflammatory bowel disease.Communications biology · 2022Article
- Anorectal Strictures in Complex Perianal CD: How to Approach?Clinics in colon and rectal surgery · 2022Review
- When disease extent is not always a key parameter: Management of refractory ulcerative proctitis.Current research in pharmacology and drug discovery · 2022Review
- 3D printed tacrolimus suppositories for the treatment of ulcerative colitis.Asian journal of pharmaceutical sciences · 2021Article
- 3D Printed Tacrolimus Rectal Formulations Ameliorate Colitis in an Experimental Animal Model of Inflammatory Bowel Disease.Biomedicines · 2020Article
- Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort.United European gastroenterology journal · 2020Article
- Simple water-based tacrolimus enemas for refractory proctitis.JGH open : an open access journal of gastroenterology and hepatology · 2020Article
- A Comprehensive Review of Topical Therapies for Distal Ulcerative Colitis.Gastroenterology & hepatology · 2020Article
- Swallowed Topical Tacrolimus Induces Clinical and Histological Remission in a Subset of Patients with Severe Lymphocytic Esophagitis.Inflammatory intestinal diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUlcerative proctitis may often be managed with topical salicylates or steroids alone, but in some patients, symptoms are persistent and severe. We analyzed the efficacy of tacrolimus suppositories in patients who had proven refractory to combined topical and systemic treatment.
methodsIn this retrospective analysis, ulcerative colitis activity index (CAI), side effects, co-medication and drug levels were assessed in 43 patients with distal ulcerative colitis who received suppositories containing 2 mg of tacrolimus b.i.d. as add-on medication.
resultsA total of 23 patients with ulcerative proctitis presented to follow-up within ≤50 days (mean 27.0 days) after suppositories were started. A decrease in CAI (from 8.0 to 5.5 points) was observed and 52.3% reached clinical remission (CAI ≤4). In total, 43 patients were available for analysis, of whom 9 had inflammation of the sigmoid colon as well. For the entire cohort, the median treatment duration was 76 days; 60% were in remission on the last documented visit. Serum measurements revealed a substantial tacrolimus level with a mean of 5.5 ng/mL. We observed one case of mild reversible acute kidney injury.
conclusionsIn ulcerative proctitis, adding tacrolimus suppositories can be an effective and safe option when topical mesalazine, corticoid formulations and concomitant oral or parenteral medications have failed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.